$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

$imuc Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000162828016013931 Filed on March 30, 2016

Income Statement

Concept	2016 Q1	2014 Q4	2013
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.100M	$920.0K	$4.121M
YoY Change	0.0%	-14.81%	0.13%
% of Gross Profit
Research & Development	$4.738M	$1.320M	$5.340M
YoY Change	129.4%	-7.69%	-30.75%
% of Gross Profit
Depreciation & Amortization	$20.37K	$10.00K	$50.40K
YoY Change	204.35%	0.0%	9.99%
% of Gross Profit
Operating Expenses	$5.837M	$2.240M	$9.460M
YoY Change	88.24%	-10.76%	-20.01%
Operating Profit	-$5.837M		-$9.460M
YoY Change	88.24%		-20.01%
Interest Expense	$264.8K	$110.0K	$0.00
YoY Change		-95.82%	-100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$5.633M	-$2.130M	-$8.801M
YoY Change	295.37%	-1875.0%	-39.29%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.633M	-$2.127M	-$8.801M
YoY Change	295.37%	-1918.13%	-39.29%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.03	-$0.16
Diluted Earnings Per Share	-$2.469M	-$0.03	-$0.16
COMMON SHARES
Basic Shares Outstanding	91.73M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2014 Q4	2013
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.51M	$23.22M	$27.65M
YoY Change	-49.64%	-16.02%	5.45%
Cash & Equivalents	$17.51M	$23.22M	$27.65M
Short-Term Investments
Other Short-Term Assets	$612.4K	$1.220M	$763.3K
YoY Change	-61.96%	59.82%	6.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$19.45M	$24.44M	$28.41M
YoY Change	-46.54%	-13.97%	5.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$164.6K	$47.37K	$66.44K
YoY Change	311.42%	-28.71%	-12.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.080M	$583.5K	$464.6K
YoY Change	823.64%	25.59%	3857.33%
Total Long-Term Assets	$5.245M	$736.4K	$531.0K
YoY Change	774.15%	38.67%	503.31%
TOTAL ASSETS
Total Short-Term Assets	$19.45M	$24.44M	$28.41M
Total Long-Term Assets	$5.245M	$736.4K	$531.0K
Total Assets	$24.69M	$25.18M	$28.94M
YoY Change	-33.23%	-13.0%	7.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$920.0K	$322.0K	$861.0K
YoY Change	87.76%	-62.6%	17.49%
Accrued Expenses	$1.136M	$632.7K	$541.3K
YoY Change	14.79%	243.88%	48.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.272M	$1.289M	$1.402M
YoY Change	52.48%	-8.06%	27.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.890M	$600.0K	$1.065M
YoY Change	88.78%	-43.4%	-62.68%
Total Long-Term Liabilities	$5.890M	$600.0K	$1.065M
YoY Change	88.78%	-43.4%	-62.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.272M	$1.289M	$1.402M
Total Long-Term Liabilities	$5.890M	$600.0K	$1.065M
Total Liabilities	$8.163M	$1.887M	$2.467M
YoY Change	77.07%	-23.61%	-37.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$79.77M	-$61.35M
YoY Change		18.04%
Common Stock	$96.30M	$84.64M
YoY Change	1.23%	1470851.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.53M	$23.29M	$26.47M
YoY Change
Total Liabilities & Shareholders Equity	$24.69M	$25.18M	$28.94M
YoY Change	-33.23%	-13.0%	7.11%

Cashflow Statement

Concept	2016 Q1	2014 Q4	2013
OPERATING ACTIVITIES
Net Income	-$5.633M	-$2.127M	-$8.801M
YoY Change	295.37%	-1918.13%	-39.29%
Depreciation, Depletion And Amortization	$20.37K	$10.00K	$50.40K
YoY Change	204.35%	0.0%	9.99%
Cash From Operating Activities	-$5.351M	-$2.110M	-$8.787M
YoY Change	75.44%	-22.99%	-29.02%
INVESTING ACTIVITIES
Capital Expenditures	$4.015K	$0.00	$44.37K
YoY Change	128.38%		351.49%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities	-$4.015K	$0.00	-$44.37K
YoY Change			351.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$264.7K	1.810M	10.26M
YoY Change	-98.19%	90.53%	-67.89%
NET CHANGE
Cash From Operating Activities	-$5.351M	-2.110M	-8.787M
Cash From Investing Activities	-$4.015K	0.000	-44.37K
Cash From Financing Activities	$264.7K	1.810M	10.26M
Net Change In Cash	-$5.090M	-300.0K	1.430M
YoY Change	-144.07%	-83.24%	-92.69%
FREE CASH FLOW
Cash From Operating Activities	-$5.351M	-$2.110M	-$8.787M
Capital Expenditures	$4.015K	$0.00	$44.37K
Free Cash Flow	-$5.355M	-$2.110M	-$8.832M
YoY Change	75.47%	-22.99%	-28.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Type DocumentType	10-K
CY2014	imuc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	1.79
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	91727797	shares
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	0.07
CY2014	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	0.02
CY2015	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	0.08
CY2012	imuc	Charge To Financing Expense ChargeToFinancingExpense	397294	USD
CY2013	imuc	Charge To Financing Expense ChargeToFinancingExpense	0	USD
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0000822411
CY2015	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q2	dei	Entity Public Float EntityPublicFloat	42419767	USD
CY2015	dei	Entity Registrant Name EntityRegistrantName	ImmunoCellular Therapeutics, Ltd.
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Trading Symbol TradingSymbol	IMUC
CY2012Q1	imuc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	1.87
CY2012Q4	imuc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	1.87
CY2015Q1	imuc	Adjusted Exercise Price Of Warrants AdjustedExercisePriceOfWarrants	1.44
CY2014	imuc	Charge To Financing Expense ChargeToFinancingExpense	62683	USD
CY2015	imuc	Charge To Financing Expense ChargeToFinancingExpense	88939	USD
CY2015Q1	imuc	Common Stock And Warrants Issued For Cash Per Share CommonStockAndWarrantsIssuedForCashPerShare	0.60
CY2012Q4	imuc	Common Stock Of Public Offering CommonStockOfPublicOffering	2823670	shares
CY2015Q1	imuc	Common Stock Of Public Offering CommonStockOfPublicOffering	3666836	shares
CY2014	imuc	Common Stock Of Public Offering CommonStockOfPublicOffering	2949867	shares
CY2012Q1	imuc	Common Stock Shares Issuable Private Placement Warrants CommonStockSharesIssuablePrivatePlacementWarrants	4744718	shares
CY2015Q4	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	3666836	shares
CY2012Q4	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	2823670	shares
CY2012Q4	imuc	Common Stock Warrants Exercise Price Investor Relations Agreement CommonStockWarrantsExercisePriceInvestorRelationsAgreement	2.65
CY2012Q1	imuc	Common Stock Warrants Exercise Price Private Placement CommonStockWarrantsExercisePricePrivatePlacement	1.41
CY2013	imuc	Common Stock Warrants Exercise Price Private Placement CommonStockWarrantsExercisePricePrivatePlacement	0.93
CY2014	imuc	Common Stock Warrants Exercise Price Private Placement CommonStockWarrantsExercisePricePrivatePlacement	0.73
CY2015	imuc	Common Stock Warrants Exercise Price Private Placement CommonStockWarrantsExercisePricePrivatePlacement	0.36
CY2015	imuc	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Not Yet Recognized Period For Recognition Maximum EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognitionMaximum	P14M
CY2013	imuc	Exercise Of Warrants ExerciseOfWarrants	6176336	USD
CY2014	imuc	Exercise Of Warrants ExerciseOfWarrants	0	USD
CY2013	imuc	Increase Decreasein Deferred Financing Costs IncreaseDecreaseinDeferredFinancingCosts	0	USD
CY2014	imuc	Increase Decreasein Deferred Financing Costs IncreaseDecreaseinDeferredFinancingCosts	0	USD
CY2015	imuc	Increase Decreasein Deferred Financing Costs IncreaseDecreaseinDeferredFinancingCosts	15041	USD
CY2013Q2	imuc	Listing Of Shares Of Common Stock In Connection With Sales Agreement ListingOfSharesOfCommonStockInConnectionWithSalesAgreement	10593220	shares
CY2015	imuc	Maximum Exercisable Period Of Options MaximumExercisablePeriodOfOptions	P10Y
CY2015	imuc	Maximum Exercisable Period Of Options If Percentage Of Common Stock Voting Rights Held Is More Than Ten Percent MaximumExercisablePeriodOfOptionsIfPercentageOfCommonStockVotingRightsHeldIsMoreThanTenPercent	P5Y
CY2015	imuc	Minimum Percentage Of Fair Market Value Of Common Stock MinimumPercentageOfFairMarketValueOfCommonStock	less than 110%
CY2015	imuc	Net Operating Losses Expire Date NetOperatingLossesExpireDate	expire in 2022 and 2016
CY2013	imuc	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	0	USD
CY2014	imuc	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	105563	USD
CY2015	imuc	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	33936	USD
CY2015	imuc	Nonrefundable And Noncreditable License And Maintenance Fee NonrefundableAndNoncreditableLicenseAndMaintenanceFee	P12M
CY2015	imuc	Percentage Of Annual Increase Of Monthly Base Rent PercentageOfAnnualIncreaseOfMonthlyBaseRent	0.03
CY2015	imuc	Percentage Of Common Stock Voting Rights Held PercentageOfCommonStockVotingRightsHeld	more than 10%
CY2015	imuc	Percentage Of Fair Market Value Of Common Stock PercentageOfFairMarketValueOfCommonStock	not be less than 100%
CY2014Q4	imuc	Proceed From Licensing Intellectual Property ProceedFromLicensingIntellectualProperty	11000000	USD
CY2013	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	4906078	USD
CY2014	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	4496322	USD
CY2015	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	14599627	USD
CY2012Q1	imuc	Public Offering Expenses PublicOfferingExpenses	1100000	USD
CY2012Q4	imuc	Public Offering Expenses PublicOfferingExpenses	1600000	USD
CY2013Q2	imuc	Rate Of Commission RateOfCommission	0.030
CY2013	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
CY2014	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
CY2015	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
CY2011Q1	imuc	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	5219768	shares
CY2012Q1	imuc	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	9489436	shares
CY2012Q4	imuc	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	10000000	shares
CY2015Q1	imuc	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	26650000	shares
CY2013	imuc	Warrant Liability Converted To Additional Paid In Capital Upon Exercise WarrantLiabilityConvertedToAdditionalPaidInCapitalUponExercise	1145659	USD
CY2014	imuc	Warrant Liability Converted To Additional Paid In Capital Upon Exercise WarrantLiabilityConvertedToAdditionalPaidInCapitalUponExercise	0	USD
CY2015	imuc	Warrant Liability Converted To Additional Paid In Capital Upon Exercise WarrantLiabilityConvertedToAdditionalPaidInCapitalUponExercise	0	USD
CY2013	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	642411	USD
CY2014	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	529774	USD
CY2015	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	2925258	USD
CY2010Q2	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2011Q1	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2012Q1	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2013	imuc	Warrants Exercised WarrantsExercised	1145659	USD
CY2014	imuc	Warrants Exercised WarrantsExercised	0	USD
CY2015	imuc	Warrants Exercised WarrantsExercised	0	USD
CY2013	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0	USD
CY2014	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0	USD
CY2015	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	322002	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1161258	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	632670	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	317653	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	154896	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	191089	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84632209	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	95849005	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	724215	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	654260	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	916028	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	62683	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4286314	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26108984	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19420978	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38907089	shares
CY2014Q4	us-gaap	Assets Assets	25178561	USD
CY2015Q4	us-gaap	Assets Assets	30082374	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	24442169	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	24560538	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26216668	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27646351	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23222296	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22604481	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1429683	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4424055	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-617815	USD
CY2014Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	25913893	USD
CY2015Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	21818229	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4095267	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	149000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	249000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	249000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63604823	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90310149	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63604823	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90310149	shares
CY2015Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	112040536	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	6360	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	9031	USD
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	105563	USD
CY2015Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	48977	USD
CY2013Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	2020987	USD
CY2014Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	2191000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	2599308	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15759274	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16302000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20091036	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17780261	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18493000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22690344	USD
CY2014	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-9460319	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-9858541	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-15513091	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	80000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	99000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	102000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1219873	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	797425	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44372	USD
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2014Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	356367	USD
CY2015Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4176280	USD
CY2013	us-gaap	Depreciation Depreciation	50402	USD
CY2014	us-gaap	Depreciation Depreciation	47656	USD
CY2015	us-gaap	Depreciation Depreciation	36193	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.33
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.38
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.32
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.06
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.06
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.06
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	334527	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	790487	USD
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1909361	USD
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2013	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	642411	USD
CY2014	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	529774	USD
CY2015	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	2925258	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3817	USD
CY2014	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	4	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4120603	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3889359	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4616500	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8800563	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9377533	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12790814	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	128175	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-644587	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	805320	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	175791	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	425950	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	140943	USD
CY2013	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	0	USD
CY2014	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	339259	USD
CY2015	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	3657913	USD
CY2013	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	133905	USD
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	426640	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9097	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-422448	USD
CY2013	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	0	USD
CY2014	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	227097	USD
CY2015	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	2209192	USD
CY2013	us-gaap	Interest Expense InterestExpense	0	USD
CY2014	us-gaap	Interest Expense InterestExpense	0	USD
CY2015	us-gaap	Interest Expense InterestExpense	133905	USD
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2015	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	17345	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	13917	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	19863	USD
CY2014Q4	us-gaap	Liabilities Liabilities	1886918	USD
CY2015Q4	us-gaap	Liabilities Liabilities	8362078	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25178561	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30082374	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1289199	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2269398	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	4133905	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10261272	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5541322	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	18591336	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-44372	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-28575	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-169750	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8787217	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9936802	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19039401	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-8800563	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-9377533	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-12790814	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	9460319	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	9858541	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	15513091	USD
CY2015Q4	us-gaap	Supplies Supplies	1158632	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3161558	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	712739	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4197344	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0180
CY2006Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	6000000	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	8000000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	12000000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4095267	shares
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28975	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	169750	USD
CY2014Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	227097	USD
CY2015Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1115657	USD
CY2013	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4000000	USD
CY2010Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	834455	USD
CY2011Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7460129	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9271370	USD
CY2012Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	19359553	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14500000	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	400	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	324517	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1045000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6750	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5030677	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Fair Value Disclosure PropertyPlantAndEquipmentFairValueDisclosure	11000000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	202261	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	372011	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47365	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	180922	USD
CY2015Q4	us-gaap	Rental Properties RentalProperties	8063	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5339716	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5969182	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10896591	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61346926	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-74137740	USD
CY2013	us-gaap	Revenues Revenues	0	USD
CY2014	us-gaap	Revenues Revenues	0	USD
CY2015	us-gaap	Revenues Revenues	0	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	724212	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	654260	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	916028	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.661
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9060
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.934
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0049
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0164
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9314765	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10719904	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.16
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.92
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2852880	USD
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1064810	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	597719	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.37
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.36
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.27
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	147084	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1075000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	387861	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	862287	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	547117	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1843000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.89
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.96
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10581194	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10466695	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.33
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.18
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8263962	shares
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.81
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.08
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.76
CY2010Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.50
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.67
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.28
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.54
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y4M21D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y2M16D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y5M24D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y1M14D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2013	us-gaap	Stock Issued1 StockIssued1	75000	USD
CY2014	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2015	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	829702	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	624047	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	50000	shares
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4906061	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4496322	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10296689	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	324517	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1045000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6750	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	23068014	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	26473594	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	23291643	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	21720296	USD
CY2014Q4	us-gaap	Supplies Supplies	0	USD
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1958775	USD
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54281189	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59915086	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87203675	shares
CY2015	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification</font><font style="font-family:inherit;font-size:10pt;"> - Certain prior year amounts included in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. </font></div></div>
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;">—The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-013931-index-headers.html	Edgar Link	pending
0001628280-16-013931-index.html	Edgar Link	pending
0001628280-16-013931.txt	Edgar Link	pending
0001628280-16-013931-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
imuc-123115x10k.htm	Edgar Link	pending
imuc-123115xexhibit1057.htm	Edgar Link	pending
imuc-123115xexhibit231.htm	Edgar Link	pending
imuc-123115xexhibit311.htm	Edgar Link	pending
imuc-123115xexhibit312.htm	Edgar Link	pending
imuc-123115xexhibit321.htm	Edgar Link	pending
imuc-123115xexhibit322.htm	Edgar Link	pending
imuc-20151231.xml	Edgar Link	completed
imuc-20151231.xsd	Edgar Link	pending
imuc-20151231_cal.xml	Edgar Link	unprocessable
imuc-20151231_def.xml	Edgar Link	unprocessable
imuc-20151231_lab.xml	Edgar Link	unprocessable
imuc-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

2016 Q1 Form 10-K Financial Statement

#000162828016013931 Filed on March 30, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC EOM Pharmaceutical Holdings, Inc. Stock $imuc

2016 Q1 Form 10-K Financial Statement

#000162828016013931 Filed on March 30, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc